公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2005 | Cell apoptosis induced by a synthetic carbazole compound LCY-2-CHO is mediated through activation of caspase and mitochondrial pathways | Hsu M.-J.; Chao Y.; Chang Y.-H.; Ho F.-M.; Huang L.-J.; Huang Y.-L.; TIEN-YAU LUH ; Chen C.-P.; WAN-WAN LIN | Biochemical Pharmacology | 24 | 22 | |
2013 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) | Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG | Liver International | 69 | 60 | |
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
2022 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study | Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. | Gastric Cancer | 7 | 7 | |
2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. | Gastric Cancer | 43 | 39 | |
2016 | Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer | Chiang N.-J.; CHIUN HSU ; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. | Scientific Reports | 18 | 15 | |
2021 | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 | Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG ; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. | Cancer | 13 | 17 | |
2015 | High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms | Chen M.-H.; Kuo Y.-J.; Yeh Y.-C.; Lin Y.-C.; Tzeng C.-H.; Liu C.-Y.; Chang P.M.H.; Chen M.-H.; YUNG-MING JENG ; Chao Y. | Journal of the Chinese Medical Association | 29 | 21 | |
2019 | Hotspot analysis and improvement schemes for capacitive deionization (CDI) using life cycle assessment | Shiu H.-Y.; Lee M.; Chao Y.; Chang K.-C.; Hou C.-H. ; PEI-TE CHIUEH | Desalination | 18 | 17 | |
2002 | Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid | Chen C.-W.; Chao Y.; Chang Y.-H.; Hsu M.-J.; WAN-WAN LIN | British Journal of Pharmacology | 37 | 37 | |
2015 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Chen J.S.; CHIH-HUNG HSU ; Chiang N.J.; Tsai C.S.; Tsou H.H.; Huang S.F.; Bai L.Y.; Chang I.C.; Shiah H.S.; Ho C.L.; Yen C.J.; Lee K.D.; Chiu C.F.; Rau K.M.; Yu M.S.; Yang Y.; Hsieh R.K.; Chang J.Y.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Wei T.-C.; on behalf of the Taiwan Cooperative Oncology Group | Annals of Oncology | 131 | 115 | |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2004 | Mechanism of LIGHT/interferon-γ-induced cell death in HT-29 cells | Chang Y.-H.; Chao Y.; Hsieh S.-L.; WAN-WAN LIN | Journal of Cellular Biochemistry | 21 | 20 | |
2014 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer | Chao Y.; Hsieh J.-S.; Yeh H.-T.; Su Y.-C.; Wu C.-C.; Chen J.-S.; Tai C.-J.; Bai L.-Y.; KUN-HUEI YEH ; Su W.-C.; Li C.-P. | Cancer Chemotherapy and Pharmacology | 12 | 9 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 168 | 154 | |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1656 | 1458 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2013 | Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase | Wu C.-A.; Chao Y.; Shiah S.-G.; WAN-WAN LIN | Biochimica et Biophysica Acta - Molecular Cell Research | 83 | 79 | |
2006 | An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer | Chao Y.; Li C.P.; Chao T.Y.; Su W.C.; Hsieh R.K.; Wu M.F.; KUN-HUEI YEH ; Kao W.Y.; Chen L.T.; ANN-LII CHENG | British Journal of Cancer | 13 | 13 | |